The Netherlands Cancer Institute

Kutatók

• RFRemond J A Fijneman

Futó vizsgálatok

• Toboroz

  Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

  NCT07436858· 1. fázis· The Netherlands Cancer Institute· Forrás

• Toboroz

  Phase 1 Study of PF-08046033 in Advanced Solid Tumors

  NCT07519655· 1. fázis· Pfizer· Forrás

• Toboroz

  A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

  NCT07535112· 1. fázis· Bayer· Forrás

• Toboroz

  PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).

  2025-523781-25-00· 1. fázis· CimCure B.V.· Forrás

• Toboroz

  Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer

  NCT07472868· 3. fázis· Catharina Ziekenhuis Stichting· Forrás

• Még nem toboroz

  IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

  2025-521908-22-00· 2/3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás

• Toboroz

  Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas

  NCT07071727· The Netherlands Cancer Institute· Forrás

• Toboroz

  Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions

  NCT07391982· The Netherlands Cancer Institute· Forrás

• Toboroz

  TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer

  NCT06931769· The Netherlands Cancer Institute· Forrás

• Toboroz

  Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

  NCT07100730· 3. fázis· Telix Pharmaceuticals (Innovations) Pty Limited· Forrás

• Toboroz

  Contrast-enhanced Ultrasound for Sentinel Node Detection

  NCT07310758· 2/3. fázis· The Netherlands Cancer Institute· Forrás

• Toboroz

  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· 3. fázis· Arcus Biosciences, Inc.· Forrás

• Toboroz

  A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

  NCT07169734· 1/2. fázis· Alentis Therapeutics AG· Forrás

• Toboroz

  Prospective Data Collection Initiative on Thoracic Malignancies

  NCT06996249· Dutch Society of Physicians for Pulmonology and Tuberculosis· Forrás

• Toboroz

  [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer

  NCT07018661· 2/3. fázis· Leiden University Medical Center· Forrás

• Toboroz

  Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

  NCT06486883· 2. fázis· MedSIR· Forrás

• Toboroz

  Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

  NCT06960577· 2. fázis· AstraZeneca· Forrás

• Toboroz

  The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer

  NCT07460180· 1/2. fázis· The Netherlands Cancer Institute· Forrás

• Toboroz

  Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

  NCT06401824· 2. fázis· Maastricht University Medical Center· Forrás

• Toboroz

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· 3. fázis· Eli Lilly and Company· Forrás

• Toboroz

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· 3. fázis· Daiichi Sankyo· Forrás

• Toboroz

  A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  NCT06914128· 1/2. fázis· Bayer· Forrás

• Toboroz

  The Radium-select Study

  NCT06659926· The Netherlands Cancer Institute· Forrás

• Toboroz

  A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  NCT06618287· 1/2. fázis· Bristol-Myers Squibb· Forrás

• Toboroz

  Earlier Detection and Optimization of Treatment and Prognosis for Patients With Early-onset Colorectal Cancer

  NCT06568679· The Netherlands Cancer Institute· Forrás

• Meghívásos bevonás

  Automated Detection of Brain Metastases on MRI

  NCT06727032· Robovision BV· Forrás

• Toboroz

  First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

  NCT06644755· 1. fázis· Daiichi Sankyo· Forrás

• Még nem toboroz

  Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with isolated resectable colorectal peritoneal metastases: a multicentre, phase II trial (INTERACT-PLUS)

  2024-512318-16-00· 2. fázis· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Forrás

• Toboroz

  Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

  NCT06567015· 1/2. fázis· Pierre Fabre Medicament· Forrás

• Toboroz

  Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

  NCT07377747· Australia and New Zealand Sarcoma Association· Forrás

• Toboroz

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· 3. fázis· Amgen· Forrás

• Toboroz

  A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  NCT06312176· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients

  NCT06082492· Radboud University Medical Center· Forrás

• Toboroz

  PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)

  NCT06875258· 4. fázis· The Netherlands Cancer Institute· Forrás

• Toboroz

  Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.

  NCT05333523· 3. fázis· Radboud University Medical Center· Forrás

• Toboroz

  Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm

  NCT05779631· Radboud University Medical Center· Forrás

• Fut, nem toboroz

  Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

  NCT05607550· 3. fázis· ArriVent BioPharma, Inc.· Forrás

• Fut, nem toboroz

  Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer

  NCT05705921· The Netherlands Cancer Institute· Forrás

• Fut, nem toboroz

  Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers

  NCT05131919· 2. fázis· The Netherlands Cancer Institute· Forrás

• Még nem toboroz

  Addition of a Focal Boost in External Beam Radiotherapy for Locally Advanced Prostate Cancer by Online Adaptive MR-guided Radiotherapy

  NCT05373316· 2. fázis· Radboud University Medical Center· Forrás

• Toboroz

  Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

  NCT05522660· 3. fázis· ETOP IBCSG Partners Foundation· Forrás

• Toboroz

  A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

  NCT05208762· 1. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás

• Toboroz

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás

• Fut, nem toboroz

  Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy

  NCT04711330· Leiden University Medical Center· Forrás

• Fut, nem toboroz

  Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

  NCT05352672· 3. fázis· Regeneron Pharmaceuticals· Forrás

• Toboroz

  A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

  NCT05384626· 1/2. fázis· Nuvalent Inc.· Forrás

• Fut, nem toboroz

  Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer

  NCT05148546· 2. fázis· The Netherlands Cancer Institute· Forrás

• Toboroz

  The Prognostic Role of Lymph Node Dissection In Men With Prostate Cancer Treated With Radical Prostatectomy

  NCT05109910· The Netherlands Cancer Institute· Forrás

• Toboroz

  Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

  NCT05255653· 3. fázis· Leiden University Medical Center· Forrás

• Fut, nem toboroz

  Induction Chemotherapy for Locally Advanced Rectal Cancer

  NCT04838496· 2. fázis· Catharina Ziekenhuis Eindhoven· Forrás

Showing 50 of 76.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák15 toboroz
• Vastagbélrák10 toboroz
• Hólyagrák6 toboroz
• Prosztatarák6 toboroz
• Gyomor- és nyelőcsőrák5 toboroz
• Fej-nyaki daganatok4 toboroz
• Melanóma4 toboroz
• Szarkóma4 toboroz
• Áttétes emlőrák3 toboroz
• Brain metastases3 toboroz
• Gyermekkori daganatok3 toboroz
• Hasnyálmirigyrák3 toboroz
• Máj- és epeúti rák3 toboroz
• Tripla negatív emlőrák3 toboroz
• Glioblasztóma2 toboroz
• Méhtestrák2 toboroz
• Mezotelióma1 toboroz
• Petefészekrák1 toboroz
• Thymoma and thymic carcinoma1 toboroz
• Vesedaganat1 toboroz

Lezárt vizsgálatok

• Lezárult

  A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors

  2024-514745-10-00· 1. fázis· Pfizer Inc.· Forrás

• Lezárult

  A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced lung cancer.

  NCT06173505· 1/2. fázis· Xencor Inc.· Forrás

• Lezárult

  Navigated Partial Nephrectomy

  NCT07315100· The Netherlands Cancer Institute· Forrás

• Visszavonták

  JDQ443 for KRAS G12C NSCLC Brain Metastases

  NCT05999357· 2. fázis· Maastricht University Medical Center· Forrás

• Lezárult

  A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL

  NCT06284304· The Netherlands Cancer Institute· Forrás

• Fut, nem toboroz

  Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

  NCT05853575· 2. fázis· Mirati Therapeutics Inc.· Forrás

• Lezárult

  A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

  NCT05383170· 1/2. fázis· Cytovation AS· Forrás

• Lezárult

  A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C Mutation

  NCT05480865· 1. fázis· Navire Pharma Inc.· Forrás

• Fut, nem toboroz

  Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study

  NCT05491616· 2. fázis· Erasmus Medical Center· Forrás

• Lezárult

  Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

  NCT05458856· 3. fázis· Ipsen· Forrás

• Lezárult

  A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal Cancer

  NCT05328908· 3. fázis· Bristol Myers Squibb International Corporation· Forrás

• Leállították

  Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)

  NCT04908956· 2. fázis· ETOP IBCSG Partners Foundation· Forrás

• Fut, nem toboroz

  HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

  NCT05338970· 3. fázis· Daiichi Sankyo· Forrás

• Lezárult

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· 2/3. fázis· Boehringer Ingelheim· Forrás

• Lezárult

  Multispectral Fluorescence as a Tool to Separate Healthy and Disease Related Lymphatic Anatomies in Prostate Cancer.

  NCT05120973· The Netherlands Cancer Institute· Forrás

• Lezárult

  MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

  NCT05007106· 2. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

  NCT04826003· 1. fázis· Hoffmann-La Roche· Forrás

• Leállították

  (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

  NCT04862780· 1. fázis· Blueprint Medicines Corporation· Forrás

• Lezárult

  Threedimensional Multiparametric Ultrasound for Prostate Cancer Detection

  NCT04605276· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Forrás

• Lezárult

  Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

  NCT04925284· 1. fázis· Exelixis· Forrás

• Leállították

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· 1/2. fázis· Merus B.V.· Forrás

• Lezárult

  Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

  NCT04644237· 2. fázis· Daiichi Sankyo· Forrás

• Fut, nem toboroz

  HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

  NCT04619004· 2. fázis· Daiichi Sankyo· Forrás

• Lezárult

  A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

  NCT03906071· 3. fázis· Mirati Therapeutics Inc.· Forrás

• Lezárult

  Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma

  NCT04625205· 1. fázis· Biontech US Inc.· Forrás

• Lezárult

  Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

  NCT04475939· 3. fázis· GlaxoSmithKline· Forrás

• Leállították

  Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

  NCT04261777· 3. fázis· Saving Patients' Lives Medical B.V.· Forrás

• Fut, nem toboroz

  A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

  NCT04211337· 3. fázis· Loxo Oncology, Inc.· Forrás

• Lezárult

  Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

  NCT04068181· 2. fázis· Amgen· Forrás

• Lezárult

  Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

  NCT03945773· 2. fázis· Ipsen· Forrás

• Lezárult

  Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

  NCT05993299· 2. fázis· USWM, LLC (dba US WorldMeds)· Forrás

• Lezárult

  Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

  NCT06703346· 2. fázis· USWM CT, LLC· Forrás

• Lezárult

  A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

  NCT03940703· 2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás

• Fut, nem toboroz

  Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

  NCT03970746· 1/2. fázis· PDC*line Pharma SAS· Forrás

• Fut, nem toboroz

  A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

  NCT04008030· 3. fázis· Bristol-Myers Squibb· Forrás

• Lezárult

  An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

  NCT03915951· 2. fázis· Pfizer· Forrás

• Leállították

  IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

  NCT03705403· 2. fázis· Maastricht University Medical Center· Forrás

• Leállították

  Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

  NCT04287894· 1. fázis· The Netherlands Cancer Institute· Forrás

• Lezárult

  A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

  NCT03661320· 3. fázis· Bristol-Myers Squibb· Forrás

• Lezárult

  Study to Evaluate CCS1477 in Advanced Tumours

  NCT03568656· 1/2. fázis· CellCentric Ltd.· Forrás

• Lezárult

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· 3. fázis· Endocyte· Forrás

• Leállították

  DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

  NCT03505710· 2. fázis· Daiichi Sankyo· Forrás

• Lezárult

  Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

  NCT03075423· 2. fázis· Goethe University· Forrás

• Lezárult

  A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

  NCT03267316· 1/2. fázis· Cantargia AB· Forrás

• Lezárult

  Melanoma Patients Immunized with Natural DenDritic Cells

  NCT02993315· 3. fázis· Radboud University Medical Center· Forrás

• Lezárult

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· 3. fázis· Pfizer· Forrás

• Lezárult

  Vascular Fingerprint Validation Study

  NCT02573584· University Medical Center Groningen· Forrás

• Lezárult

  Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma

  NCT02278887· 3. fázis· The Netherlands Cancer Institute· Forrás

• Lezárult

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· 3. fázis· Pfizer· Forrás

Showing 50 of 51.

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Tüdőrák99 munka · 44 vizsgálat
• Prosztatarák88 munka · 18 vizsgálat
• Melanóma78 munka · 12 vizsgálat
• Vastagbélrák74 munka · 21 vizsgálat
• Hólyagrák67 munka · 8 vizsgálat
• Petefészekrák44 munka · 6 vizsgálat
• Szarkóma42 munka · 9 vizsgálat
• Vesedaganat34 munka · 8 vizsgálat
• Tripla negatív emlőrák27 munka · 8 vizsgálat
• Méhtestrák18 munka · 4 vizsgálat
• Áttétes emlőrák16 munka · 6 vizsgálat
• Fej-nyaki daganatok15 munka · 10 vizsgálat
• Mezotelióma14 munka · 1 vizsgálat
• Hodgkin-limfóma11 munka · 1 vizsgálat
• Pajzsmirigyrák9 munka · 2 vizsgálat